Bortezomib consolidation post ‐ASCT as frontline therapy for multiple myeloma deepens disease response and MRD‐negative rate whilst maintaining QOL and response to re‐treatment at relapse

British Journal of Haematology, EarlyView.
Source: British Journal of Haematology - Category: Hematology Authors: Tags: Correspondence Source Type: research